Journal
JOURNAL OF LEUKOCYTE BIOLOGY
Volume 104, Issue 1, Pages 69-83Publisher
OXFORD UNIV PRESS
DOI: 10.1002/JLB.5MR0118-028R
Keywords
biomarkers; eosinophil-related disorders; eosinophilia; hypereosinophilic syndromes; murine models; translational research
Categories
Funding
- Division of Intramural Research, NIAID, NIH [NIH K08 HL116429, UG1 HL139117]
- FDA [R01FD004086]
- NIH [R21HL118588, R01AI130033, NIH P01 HL088594, NIH R21 AI122103, NIH U19 AI070235, NIH R01 AI124355, R37 A1045898, NIH K24DK100303, NIAID-U-01 AI097073]
- APFED (HOPE Grant program)
- University of Illinois (Chancellors Innovation Fund-Proof of Concept Award) [R01 AI072265, P01 HL107151, R01 AI105839]
- Campaign Urging Research for Eosinophilic Disease (CURED) Foundation
- Buckeye Foundation
- Sunshine Charitable Foundation
- Rare Disease Clinical Research Network (RDCRN) [U54 AI117804]
- ORDR
- NCATS
- NIAID
- NIDDK
- American Partnership for Eosinophilic Disorders (APFED)
- CURED
- Eosinophilic Family Coalition (EFC)
- CEGIR [AI132840-01A1, HL065228, RAR061567A, HL124165]
- Belgian National Fund for Scientific Research [F 5/4/150/4]
- Israel Science Foundation [ISF 472/15, AI121186]
- NIHR Leicester Biomedical Research Centre
- National Institute for Health Research or the Department of Health
- NIAID [R37020241]
Ask authors/readers for more resources
Eosinophil-associated diseases (EADs) are rare, heterogeneous disorders characterized by the presence of eosinophils in tissues and/or peripheral blood resulting in immunopathology. The heterogeneity of tissue involvement, lack of sufficient animal models, technical challenges in working with eosinophils, and lack of standardized histopathologic approaches have hampered progress in basic research. Additionally, clinical trials and drug development for rare EADs are limited by the lack of primary and surrogate endpoints, biomarkers, and validated patient-reported outcomes. Researchers with expertise in eosinophil biology and eosinophil-related diseases reviewed the state of current eosinophil research, resources, progress, and unmet needs in the field since the 2012 meeting of the NIH Taskforce on the Research of Eosinophil-Associated Diseases (TREAD). RE-TREAD focused on gaps in basic science, translational, and clinical research on eosinophils and eosinophil-related pathogenesis. Improved recapitulation of human eosinophil biology and pathogenesis in murine models was felt to be of importance. Characterization of eosinophil phenotypes, the role of eosinophil subsets in tissues, identification of biomarkers of eosinophil activation and tissue load, and a better understanding of the role of eosinophils in human disease were prioritized. Finally, an unmet need for tools for use in clinical trials was emphasized. Histopathologic scoring, patient- and clinician-reported outcomes, and appropriate coding were deemed of paramount importance for research collaborations, drug development, and approval by regulatory agencies. Further exploration of the eosinophil genome, epigenome, and proteome was also encouraged. Although progress has been made since 2012, unmet needs in eosinophil research remain a priority. Review on eosinophil biology and eosinophil-related disorders (2012-2017) with a focus on continued unmet needs in eosinophil-associated diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available